Display options
Cite
Vargas JP, Díaz E, Portavella M, et al. Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes. Front Psychol. 2016;7:206doi: 10.3389/fpsyg.2016.00206.
Vargas, J. P., Díaz, E., Portavella, M., & López, J. C. (2016). Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes. Frontiers in psychology, 7206. https://doi.org/10.3389/fpsyg.2016.00206
Vargas, Juan P, et al. "Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes." Frontiers in psychology vol. 7 (2016): 206. doi: https://doi.org/10.3389/fpsyg.2016.00206
Vargas JP, Díaz E, Portavella M, López JC. Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes. Front Psychol. 2016 Feb 19;7:206. doi: 10.3389/fpsyg.2016.00206. eCollection 2016. PMID: 26925020; PMCID: PMC4759263.
Copy Download .nbib Format: NLM
Share it on

Front Psychol. 2016 Feb 19;7:206. doi: 10.3389/fpsyg.2016.00206. eCollection 2016.

Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes.

Frontiers in psychology

Juan P Vargas, Estrella Díaz, Manuel Portavella, Juan C López

Affiliations

  1. Animal Behavior and Neuroscience Lab, Department of Experimental Psychology, Universidad de Sevilla Seville, Spain.

PMID: 26925020 PMCID: PMC4759263 DOI: 10.3389/fpsyg.2016.00206

Abstract

Traditional diagnostic scales are based on a number of symptoms to evaluate and classify mental diseases. In many cases, this process becomes subjective, since the patient must calibrate the magnitude of his/her symptoms and therefore the severity of his/her disorder. A completely different approach is based on the study of the more vulnerable traits of cognitive disorders. In this regard, animal models of mental illness could be a useful tool to characterize indicators of possible cognitive dysfunctions in humans. Specifically, several cognitive disorders such as schizophrenia involve a dysfunction in the mesocorticolimbic dopaminergic system during development. These variations in dopamine levels or dopamine receptor sensibility correlate with many behavioral disturbances. These behaviors may be included in a specific phenotype and may be analyzed under controlled conditions in the laboratory. The present study provides an introductory overview of different quantitative traits that could be used as a possible risk indicator for different mental disorders, helping to define a specific endophenotype. Specifically, we examine different experimental procedures to measure impaired response in attention linked to sensorimotor gating as a possible personality trait involved in maladaptive behaviors.

Keywords: dopamine; endophenotype; latent inhibition; mental disorder; prepulse inhibition

References

  1. Biol Psychiatry. 1999 Jul 1;46(1):31-9 - PubMed
  2. Biol Psychiatry. 1999 Jul 1;46(1):40-55 - PubMed
  3. Ann N Y Acad Sci. 1999 Jun 29;877:49-63 - PubMed
  4. Biol Psychiatry. 1999 Aug 1;46(3):329-39 - PubMed
  5. Am J Psychiatry. 2000 Jan;157(1):55-9 - PubMed
  6. Brain Res Brain Res Rev. 2000 Mar;31(2-3):113-7 - PubMed
  7. Brain Res Brain Res Rev. 2000 Mar;31(2-3):179-86 - PubMed
  8. Brain Res Brain Res Rev. 2000 Mar;31(2-3):330-41 - PubMed
  9. Neurosci Biobehav Rev. 2000 Jun;24(4):417-63 - PubMed
  10. Cereb Cortex. 2000 Oct;10(10):1014-27 - PubMed
  11. Schizophr Res. 2001 Apr 15;49(1-2):171-8 - PubMed
  12. J Neurosci. 2001 Jul 1;21(13):4915-22 - PubMed
  13. Brain Res Bull. 2001 May 1;55(1):71-7 - PubMed
  14. Psychophysiology. 1975 May;12(3):238-48 - PubMed
  15. Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58 - PubMed
  16. Neuropsychopharmacology. 2002 Jul;27(1):47-54 - PubMed
  17. Prog Neurobiol. 2002 May;67(1):53-83 - PubMed
  18. Schizophr Res. 2003 Apr 1;60(2-3):285-98 - PubMed
  19. Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97 - PubMed
  20. Am J Psychiatry. 2003 Oct;160(10):1809-16 - PubMed
  21. Appetite. 2003 Oct;41(2):191-5 - PubMed
  22. Brain Cogn. 2004 Jun;55(1):116-33 - PubMed
  23. J Neurosci. 2004 Jun 2;24(22):5131-9 - PubMed
  24. Neuropsychopharmacology. 2004 Nov;29(11):2052-64 - PubMed
  25. Prog Neurobiol. 2004 Sep;74(1):1-58 - PubMed
  26. Neuropsychopharmacology. 2005 Feb;30(2):250-60 - PubMed
  27. Arch Gen Psychiatry. 1992 Mar;49(3):206-15 - PubMed
  28. Schizophr Res. 2005 Jun 15;75(2-3):399-404 - PubMed
  29. Biol Psychiatry. 2006 Jul 15;60(2):93-105 - PubMed
  30. Eur J Neurosci. 2006 Jan;23(1):279-84 - PubMed
  31. Biol Psychiatry. 2006 Aug 1;60(3):253-64 - PubMed
  32. Cereb Cortex. 2007 May;17(5):1235-40 - PubMed
  33. Psychopharmacology (Berl). 2007 Apr;191(3):599-607 - PubMed
  34. Neuroscience. 2006 Dec 1;143(2):395-405 - PubMed
  35. EXS. 2006;98:245-78 - PubMed
  36. Neuropsychopharmacology. 2007 Feb;32(2):483-92 - PubMed
  37. Psychopharmacology (Berl). 2007 Apr;191(3):391-431 - PubMed
  38. Schizophr Bull. 2007 Jan;33(1):69-94 - PubMed
  39. Annu Rev Clin Psychol. 2010;6:155-79 - PubMed
  40. Neurobiol Learn Mem. 2008 Sep;90(2):339-46 - PubMed
  41. Psychopharmacology (Berl). 2008 Oct;200(2):205-15 - PubMed
  42. Trends Neurosci. 2008 Nov;31(11):552-8 - PubMed
  43. Biol Psychiatry. 2009 May 15;65(10):869-73 - PubMed
  44. Neurotox Res. 2009 May;15(4):311-20 - PubMed
  45. Neuropsychopharmacology. 2010 Jan;35(1):27-47 - PubMed
  46. Trends Neurosci. 2009 Oct;32(10):517-24 - PubMed
  47. Annu Rev Psychol. 1991;42:161-90 - PubMed
  48. Neuron. 2010 Mar 11;65(5):585-96 - PubMed
  49. Int J Neuropsychopharmacol. 2010 Oct;13(9):1269-84 - PubMed
  50. Nature. 2011 Jan 6;469(7328):53-7 - PubMed
  51. Curr Top Behav Neurosci. 2010;4:349-71 - PubMed
  52. Schizophr Bull. 2011 May;37(3):484-92 - PubMed
  53. J Neurosci. 2011 Jun 8;31(23):8381-94 - PubMed
  54. FASEB J. 1990 Jul;4(10):2737-44 - PubMed
  55. Annu Rev Clin Psychol. 2012;8:109-30 - PubMed
  56. Trends Cogn Sci. 2012 Jan;16(1):43-51 - PubMed
  57. Trends Cogn Sci. 2012 Jan;16(1):81-91 - PubMed
  58. Schizophr Bull. 2013 May;39(3):575-82 - PubMed
  59. Dialogues Clin Neurosci. 2012 Mar;14(1):29-37 - PubMed
  60. J Neurosci. 2012 Nov 14;32(46):16223-32 - PubMed
  61. Annu Rev Clin Psychol. 2013;9:177-213 - PubMed
  62. Eur Neuropsychopharmacol. 2013 Oct;23(10):1165-81 - PubMed
  63. Biol Psychiatry. 2013 Oct 1;74(7):490-501 - PubMed
  64. Neurobiol Learn Mem. 2014 May;111:19-25 - PubMed
  65. Psychophysiology. 2014 Dec;51(12):1285-99 - PubMed
  66. Neuropsychopharmacology. 2015 Aug;40(9):2096-102 - PubMed
  67. Psychopharmacology (Berl). 2015 Dec;232(23):4337-46 - PubMed
  68. Compr Psychiatry. 1989 Mar-Apr;30(2):121-7 - PubMed
  69. Am J Psychiatry. 1988 Apr;145(4):506-9 - PubMed
  70. J Comp Neurol. 1988 Mar 1;269(1):58-72 - PubMed
  71. Br J Psychiatry. 1973 Jan;122(566):15-30 - PubMed
  72. J Neurosci. 1995 May;15(5 Pt 1):3622-39 - PubMed
  73. Psychol Bull. 1995 Jan;117(1):87-103 - PubMed
  74. Neuropsychopharmacology. 1993 Aug;9(1):67-75 - PubMed
  75. Psychopharmacology (Berl). 1995 Nov;122(1):27-34 - PubMed
  76. Curr Opin Neurobiol. 1996 Apr;6(2):228-36 - PubMed
  77. Schizophr Res. 1996 May;20(1-2):91-103 - PubMed
  78. Behav Brain Res. 1996 Aug;78(2):211-23 - PubMed
  79. Neuroscience. 1996 Nov;75(2):535-42 - PubMed
  80. Neuropsychopharmacology. 1996 Dec;15(6):587-94 - PubMed
  81. Am J Med Genet. 1997 Feb 21;74(1):104-11 - PubMed
  82. Psychopharmacology (Berl). 1997 Aug;132(3):303-10 - PubMed
  83. Nat Genet. 1997 Oct;17(2):127-9 - PubMed
  84. Schizophr Bull. 1997;23(3):509-12 - PubMed
  85. Physiol Rev. 1998 Jan;78(1):189-225 - PubMed
  86. Schizophr Bull. 1998;24(2):267-83 - PubMed
  87. Brain Res Brain Res Rev. 1998 Dec;28(3):309-69 - PubMed

Publication Types